Takeda Pharmaceuticals (formerly Nycomed)
Pharmaceutical Manufacturing • 
Glattpark, Zurich, Switzerland • 501-1000 Employees
Company overview
| Headquarters | Thurgauerstrasse 130, Zurich, 8152, CH |
| Phone number | +4119952025 |
| Websites | |
| NAICS | 3254 |
| Keywords | Emerging Markets, Gastroenterology, Osteoporosis, Pain, Respiratory, Tissue Management, Specialty Pharmaceuticals, Inflammatory Diseases, Partnerships And Licensing |
| Employees | 501-1000 |
| Socials |
Key Contacts at Takeda Pharmaceuticals (formerly Nycomed)
Bader E. Hussaini
Senior Medical Director; Medical Affairs. Global Medical Lead Entyvio & New Programs Ibd
Vinay Potdar
Associate Director Finance & Company Secretary
Dinesh Gopalakrishnan
Senior Director, Business Excellence
Mike Baratta
Senior Director, Head Of Mass Spectrometry-Clinical Bioanalysis
Ali Khan
Director Procurement - India, Cis, Middle East And Africa
Christa Conlin
Associate Director It Procurement
Frank Campana
Executive Medical Director. Global Clinical Lead Cell Therapy
Gitte Hjelvang
Director Quality Assurance/Qp
Michael Chapman
Director, North America Distribution & Logistics
Clarisse Hollifield
Associate Director, Patient Services, Gattex-Oas
Takeda Pharmaceuticals (formerly Nycomed) Email Formats
Takeda Pharmaceuticals (formerly Nycomed) uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@takeda.com), used 67% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@takeda.com | 67% |
{first name}.{last name} | john.doe@takeda.com | 32.1% |
About Takeda Pharmaceuticals (formerly Nycomed)
On October 1, 2011, Takeda Pharmaceutical Company Limited acquired Nycomed. Through the acquisition, Takeda, the largest pharma company in Asia, broadened its coverage of the global pharmaceutical market, especialy in Europe and emergig markets. More information on http://www.takeda.com. The below information is from before the acquisition: Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio. Its R&D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy. Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners. Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.
Takeda Pharmaceuticals (formerly Nycomed) revenue & valuation
| Annual revenue | $71,300,000 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $228,100,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 501-1000
Seniority
Employees
Employees by Department
Takeda Pharmaceuticals (formerly Nycomed) has 446 employees across 19 departments.
Departments
Number of employees
Funding Data
Takeda Pharmaceuticals (formerly Nycomed) has never raised funding before.
Canada
Italy
Croatia
Frequently asked questions
4.8
40,000 users
